Angiogenesis as a new target for cancer control

European Journal of Cancer, Supplement

Volumn 1, Issue 2, 2003, Pages 1-12

  Harris, A L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Anti angiogenesis Inhibitors; Hypoxia; Trials; VEGF

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; ADRENOMEDULLIN; AE 941; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOZYME; ANTINEOPLASTIC AGENT; CGS 27023A; CILENGITIDE; CM 101; ENDOTHELIN; EPHRIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IM 862; IRINOTECAN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PRINOMASTAT; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; REBIMASTAT; RECOMBINANT ALPHA INTERFERON; SEMAXANIB; SOLIMASTAT; TANOMASTAT; THROMBOSPONDIN; TNP 70; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB; ZD 0101; ZK 22584;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CANCER CONTROL; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE SEVERITY; DOWN REGULATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; GENE FUNCTION; HOX GENE; HUMAN; HYPOXIA; MUTATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TUMOR; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 2442447195     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00007-7     Document Type: Article

References (131)

1. Folkman J. What is the evidence that tumours are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6
2. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 55:2000;15-36
3. Boehm T., Folkman J., Browder T., Oreilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug-resistance. Nature. 390:1997;404-407
4. Ellis L.M., Liu W.B., Ahmad S.A., et al. Overview of angiogenesis. biologic implications for antiangiogenic therapy Semin. Oncol. 28:2001;94-104
5. Webb C.P., Woude G.F.V. Genes that regulate metastasis and angiogenesis. J. Neurooncol. 50:2000;71-87
6. Maio M., Altomonte M., Calabro L., Fonsatti E. Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies. Front Biosci. 6:2001;D776-D784
7. Robert E.G., Hunt J.D. Lipid messengers as targets for antiangiogenic therapy. Curr. Pharm. Des. 7:2001;1615-1626
8. Eatock M.M., Schatzlein A., Kaye S.B. Tumour vasculature as a target for anticancer therapy. Cancer Treat. Rev. 26:2000;191-204
9. Sato Y. Molecular mechanism of angiogenesis - transcription factors and their therapeutic relevance. Pharmacol. Ther. 87:2000;51-60
10. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:1999;9-22
11. Hamby J.M., Showalter H.D.H. Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol. Ther. 82:1999;169-193
12. Mousa S.A. Anti-integrins as a potential therapeutic target in angiogenesis. Expert Opin. Ther. Pat. 9:1999;1237-1248
13. Geng L., Donnelly E., McMahon G., Lin P.C., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61:2001;2413-2419
14. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 23:2001;263-272
15. Ambartsumian N., Klingelhofer J., Grigorian M., et al. The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene. 20:2001;4685-4695
16. Browder T., Folkman J., PirieShepherd S. The hemostatic system as a regulator of angiogenesis. J. Biol. Chem. 275:2000;1521-1524
17. Cao R.H., Brakenhielm E., Wahlestedt C., Thyberg J., Cao Y.H. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc. Natl. Acad. Sci. USA. 98:2000;6390-6395
18. Funasaka T., Haga A., Raz A., Nagase H. Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochem. Biophys. Res. Commun. 284:2001;1116-1125
19. Hu Y.L., Tee M.K., Goetzl E.J., et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 93:2001;762-768
20. Pola R., Ling L.E., Silver M., et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 7:2001;706-711
21. Shimo T., Kubota S., Kondo S., et al. Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett. 174:2001;57-64
22. Vikhanskaya F., Bani M.R., Borsotti P., et al. p73 overexpression increases VEGF and reduces thrombospondin-1 production. implications for tumor angiogenesis Oncogene. 20:2001;7293-7300
23. Liu C.Y., Paradis H., Gendron R., et al. AngX/CDT-6, a novel factor that enhances angiogenesis. Mol. Biol. Cell. 11:2000;66A
24. Marneros A.G., Olsen B.R. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 20:2001;337-345
25. NangiaMakker P., Honjo Y., Sarvis R., et al. Galectin-3 induces endothetial cell morphogenesis and angiogenesis. Am. J. Pathol. 156:2000;899-909
26. Talks K.L., Harris A.L. Current status of antiangiogenic factors. Br. J. Haematol. 109:2000;477-489
27. Jones N., Iljin K., Dumont D.J., Alitalo K. Tie receptors. New modulators of angiogenic and lymphangiogenic responses Nat. Rev. Mol. Cell. Biol. 2:2001;257-267
28. Powers C.J., McLeskey S.W., Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr-Relat. Cancer. 7:2000;165-197
29. LeCouter J., Kowalski J., Foster J., et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature. 412:2001;877-884
30. Lee M.S., Moon E.J., Lee S.W., Kim H.S., Kim K.W., Kim Y.J. Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res. 61:2001;3290-3293
31. Lawler J., Miao W.M., Duquette M., Bouck N., Bronson R.T., Hynes R.O. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am. J. Pathol. 159:2001;1949-1956
32. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin. an endogenous inhibitor of angiogenesis and tumor growth Cell. 88:1997;277-285
33. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin. a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell. 79:1994;315-328
34. de F.-F., Nicholson A.C., Feige J.J., Van M.E.G. Thrombospondins and tumor angiogenesis. Trends Mol. Med. 7:2001;401-407
35. Kim M.S., Kwon H.J., Lee Y.M., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7:2001;437-443
36. Larsson H., Akerud P., Nordling K., Raub S.E., Claesson W.L., Bjork I. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J. Biol. Chem. 276:2001;11996-12002
37. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P., et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl. Acad. Sci. USA. 97:2000;9624-9629
38. Glienke J., Fenten G., Seemann M., Sturz A., Thierauch K.H. Human SPRY2 inhibits FGF2 signalling by a secreted factor. Mech. Dev. 96:2000;91-99
39. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364
40. Holmgren L., Oreilly M.S., Folkman J. Dormancy of micrometastases- balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:1995;149-153
41. Sage E.H. Pieces of 8- bioactive fragments of extracellular proteins as regulators of angiogenesis. Trends Cell Biol. 7:1997;182-186
42. Troyanovsky B., Levchenko T., Mansson G., Matvijenko O., Holmgren L. Angiomotin. an angiostatin binding protein that regulates endothelial cell migration and tube formation J. Cell. Biol. 152:2001;1247-1254
43. Gately S., Twardowski P., Stack M.S., et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA. 94:1997;10868-10872
44. Relf M., Lejeune S., Scott P.A.E., et al. Expression of the angiogenic factors vascular endothelial-cell growth-factor, acidic and basic fibroblast growth-factor, tumor-growth factor-beta-1, platelet-derived endothelial-cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969
45. Rak J., Yu J.L., Klement G., Kerbel R.S. Oncogenes and angiogenesis. signaling three-dimensional tumor growth J. Invest. Dermatol. Symp. Proc. 5:2000;24-33
46. Rak J., Mitsuhashi Y., Sheehan C., et al. Oncogenes and tumor angiogenesis. differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts Cancer Res. 60:2000;490-498
47. Wen S.H., Stolarov J., Myers M.P., et al. PTEN controls tumor-induced angiogenesis. Proc. Natl. Acad. Sci. USA. 98:2001;4622-4627
48. Ciardiello F., Bianco R., Damiano V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6:2000;3739-3747
49. Kumar R., Yarmand B.R. The role of HER2 in angiogenesis. Semin. Oncol. 28:2001;27-32
50. Sanchez E.T., Botella L.M., Velasco B., Corbi A., Attisano L., Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 276:2001;38527-38535
51. Rafii S. Circulating endothelial precursors. mystery, reality, and promise J. Clin. Invest. 105:2000;17-19
52. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85:1999;221-228
53. Shi Q., Rafii S., Wu M.H., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 92:1998;362-367
54. Lin Y., Weisdorf D.J., Solovey A., Hebbel R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105:2000;71-77
55. Davidoff A.M., Ng C.Y.C., Brown P., et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 7:2001;2870-2879
56. Shintani S., Murohara T., Ikeda H., et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 103:2001;2776-2779
57. Ito H., Rovira II, Bloom M.L., et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res. 59:1999;5875-5877
58. Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 97:2001;3658-3661
59. Djonov V., Schmid M., Tschanz S.A., Burri P.H. Intussusceptive angiogenesis - its role in embryonic vascular network formation. Circ. Res. 86:2000;286-292
60. Folberg R., Hendrix M.J.C., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156:2000;361-381
61. Benezra R. Role of Id proteins in embryonic and tumor angiogenesis. Trends Cardiovasc. Med. 11:2001;237-241
62. Myers C., Charboneau A., Boudreau N. Homeobox B3 promotes capillary morphogenesis and angiogenesis. J. Cell. Biol. 148:2000;343-351
63. Villa N., Walker L., Lindsell C.E., Gasson J., Iruela-Arispe M.L., Weinmaster G. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech. Dev. 108:2001;161-164
64. Cheng N., Brantley D.M., Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 13:2002;75-85
65. Adams R.H., Klein R. Eph receptors and ephrin ligands. essential mediators of vascular development. Trends Cardiovasc. Med. 10:2000;183-188
66. Carson W.E.B., Watkins D.N., Nanda A., Vogelstein B., Kinzler K.W., Croix B.S. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 61:2001;6649-6655
67. Huminiecki L., Bicknell R. In silico cloning of novel endothelial-specific genes. Genome Res. 10:2000;1796-1806
68. Giordano F.J., Johnson R.S. Angiogenesis. the role of the microenvironment in flipping the switch Curr. Opin. Genet. Dev. 11:2001;35-40
69. Hockel M., Vaupel P. Tumor hypoxia. definitions and current clinical, biologic, and molecular aspects J. Natl. Cancer Inst. 93:2001;266-276
70. Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell. Biol. 2:2000;423-427
71. Kamura T., Sato S., Iwai K., CzyzykKrzeska M., Conaway R.C., Conaway J.W. Activation of HIF1 alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. USA. 97:2000;10430-10435
72. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275
73. Stebbins C.E., Kaelin W.G. Jr., Pavletich N.P. Structure of the VHL-ElonginC-ElonginB complex. implications for VHL tumor suppressor function Science. 284:1999;455-461
74. Talks K.L., Turley H., Gatter K.C., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:2000;411-421
75. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835
76. Bos R., Zhong H., Hanrahan C.F., et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93:2001;309-314
77. Jaakkola P., Mole D.R., Tian Y.M., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:2001;468-472
78. Ivan M., Kondo K., Yang H., et al. HIF{alpha} targeted for VHL-mediated destruction by proline hydroxylation. implications for O2 sensing Science. 292(5516):2001;449-451
79. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294(5545):2001;1337-1340
80. Epstein A.C., Gleadle J.M., McNeill L.A., et al. Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54
81. Denko N., Schindler C., Koong A., Laderoute K., Green C., Giaccia A. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin. Cancer Res. 6:2000;480-487
82. Koong A.C., Denko N.C., Hudson K.M., et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 60:2000;883-887
83. Wykoff C.C., Pugh C.W., Maxwell P.H., Harris A.L., Ratcliffe P.J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene. 19:2000;6297-6305
84. Lal A., Peters H., St Croix B., et al. Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. 93:2001;1337-1343
85. Laderoute K.R., Alarcon R.M., Brody M.D., et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin. Cancer Res. 6:2000;2941-2950
86. Clarke K., Smith K., Gullick W.J., Harris A.L. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br. J. Cancer. 84:2001;1322-1329
87. Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells. implications for tumor angiogenesis and therapeutics Cancer Res. 60:2000;1541-1545
88. Blancher C., Moore J.W., Talks K.L., Houlbrook S., Harris A.L. Relationship of hypoxia-inducible factor (HIF)-1α and HIF-2α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60:2000;7106-7113
89. Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:2000;391-396
90. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1-alpha. Nature. 392:1998;405-408
91. Suzuki H., Tomida A., Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene. 20:2001;5779-5788
92. Fox S.B., Gasparini G., Harris A.L. Angiogenesis. pathological prognostic and growth-factor pathways and their link to trial design and anticancer drugs Lancet Oncol. 2:2001;278-289
93. Vermeulen P.B., Gasparini G., Fox S.B., et al. Second international concensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer. 38(12):2002;1564-1579
94. Fox S.B., Harris A.L. Markers of tumor angiogenesis- clinical- applications in prognosis and anti-angiogenic therapy. Invest. New Drugs. 15:1997;15-28
95. Koukourakis M.I., Giatromanolaki A., Thorpe P.E., et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 60:2000;3088-3095
96. Miller D.W., Graulich W., Karges B., et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer. 81:1999;568-572
97. Kumar S., Ghellal A., Li C., Byrne G., Haboubi N., Wang J.M., Bundred N. Breast carcinoma. vascular density determined using CD105 antibody correlates with tumor prognosis Cancer Res, 59:1999;856-861
98. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 125:1999;1591-1598
99. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:1999;159-165
100. Mundhenke C., Thomas J.P., Wilding G., et al. Tissue examination to monitor antiangiogenic therapy. a phase I clinical trial with endostatin Clin. Cancer Res. 7:2001;3366-3374
101. Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:1999;808-812
102. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 47:2001;617-623
103. Pinedo H.M., Verheul H.M., D'Amato R.J., Folkman J. Involvement of platelets in tumour angiogenesis? Lancet. 352:1998;1775-1777
104. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent. early effects in tumors and normal tissues Cancer Res. 59:1999;1626-1634
105. Chen Q.R., Zhang L., Gasper W., Mixson A.J. Targeting tumor angiogenesis with gene therapy. Mol. Genet. Metab. 74:2001;120-127
106. Varda B.N., Shaish A., Gonen A., et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther. 8:2001;819-827
107. Dachs G.U., Patterson A.V., Firth J.D., et al. Targeting gene-expression to hypoxic tumor-cells. Nat. Med. 3:1997;515-520
108. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886
109. Gately S., Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7:2001;427-436
110. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;R15-R24
111. Halin C., Neri D. Antibody-based targeting of angiogenesis. Crit. Rev. Ther. Drug Carrier Syst. 18:2001;299-339
112. Hicklin D.J., Witte L., Zhu Z.P., et al. Monoclonal antibody strategies to block angiogenesis. Drug Discov. Today. 6:2001;517-528
113. Tille J.C., Wood J., Mandriota S.J., et al. Vascular Endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth gactor-induced angiogenesis in vivo and in vitro. J. Pharmacol. Exp. Ther. 299:2001;1073-1085
114. Dicker A.P., Williams T.L., Grant D.S. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am. J. Clin. Oncol. 24:2001;438-442
115. Weber W.A., Haubner R., Vabuliene E., et al. Tumor angiogenesis targeting using imaging agents. Q. J. Nucl. Med. 45:2001;179-182
116. Dennie J., Mandeville J.B., Boxerman J.L., et al. Nmr imaging of changes in vascular morphology due to tumor angiogenesis. Magn. Reson. Med. 40:1998;793-799
117. Pham C.D., Roberts T.P.L., Vanbruggen N., Melnyk O., et al. Magnetic-resonance-imaging detects suppression of tumor vascular-permeability after administration of antibody to vascular endothelial growth-factor. Cancer Invest. 16:1998;225-230
118. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., Li K.C.P. Detection of tumor angiogenesis in-vivo by alpha(v)beta(3)-targeted magnetic-resonance-imaging. Nat. Med. 4:1998;623-626
119. Vanzijl P.C.M., Eleff S.M., Ulatowski J.A., et al. Quantitative assessment of blood-flow, blood-volume and blood oxygenation effects in functional magnetic-resonance-imaging. Nat. Med. 4:1998;159-167
120. Lee K.H., Lee S.Y., Paik J.Y., et al. Tumor imaging with I-123 labeled angiostatin, a novel anti-angiogenesis targeted radiopharmaceutical. J. Nucl. Med. 42:2001;253P
121. Teicher B.A., Holden S.A., Ara G., et al. Potentiation of cytotoxic cancer therapies by tnp-470 alone and with other anti-angiogenic agents. Int. J. Cancer. 57:1994;920-925
122. Burke P.A., DeNardo S.J. Antiangiogenic agents and their promising potential in combined therapy. Crit. Rev. Oncol. Hematol. 39:2001;155-171
123. Smith K., Fox S.B., Whitehouse R., Taylor M., et al. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann. Oncol. 10:1999;707-713
124. Pezzella F., Pastorino U., Tagliabue E., et al. Non-small-cell-lung carcinoma tumor-growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 151:1997;1417-1423
125. Pezzella F., Manzotti M., DeBAcco A., et al. Evidence for novel non-angiogenic pathway in breast cancer metastasis. Lancet. 355:2000;1787-1788
126. Naresh K.N., Nerurkar A.Y., Borges A.M. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology. 38:2001;466-470
127. Holash J., Wiegand S.J., Yancopoulos G.D. New model of tumor angiogenesis. dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF Oncogene. 18:1999;5356-5362
128. Raza S.L., Cornelius L.A. Matrix metalloproteinases. pro- and anti-angiogenic activities J. Invest. Dermatol. Symp. Proc. 5:2000;47-54
129. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., Folkman J., Moses M.A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. 274:1999;29568-29571
130. Filleur S., Volpert O.V., Degeorges A., et al. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev. 15:2001;1373-1382
131. Dawson D.W., Volpert O.V., Pearce S.F., et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 55:1999;332-338